272 related articles for article (PubMed ID: 7614253)
1. Antitat gene therapy: a candidate for late-stage AIDS patients.
Lisziewicz J; Sun D; Lisziewicz A; Gallo RC
Gene Ther; 1995 May; 2(3):218-22. PubMed ID: 7614253
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of HIV-1 replication in chronically infected cell lines and peripheral blood mononuclear cells by retrovirus-mediated antitat gene transfer.
Li Y; Starr SE; Lisziewicz J; Ho WZ
Gene Ther; 2000 Feb; 7(4):321-8. PubMed ID: 10694813
[TBL] [Abstract][Full Text] [Related]
3. Block of HIV-1 infection by a combination of antisense tat RNA and TAR decoys: a strategy for control of HIV-1.
Chang HK; Gendelman R; Lisziewicz J; Gallo RC; Ensoli B
Gene Ther; 1994 May; 1(3):208-16. PubMed ID: 7584083
[TBL] [Abstract][Full Text] [Related]
4. Transduction of CD34+ hematopoietic progenitor cells with an antitat gene protects T-cell and macrophage progeny from AIDS virus infection.
Rosenzweig M; Marks DF; Hempel D; Lisziewicz J; Johnson RP
J Virol; 1997 Apr; 71(4):2740-6. PubMed ID: 9060627
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of antitat gene therapy in the presence of high multiplicity infection and inflammatory cytokines.
Lisziewicz J; Sun D; Gallo RC; Ensoli B; Lori F
Hum Gene Ther; 1996 Dec; 7(18):2209-16. PubMed ID: 8953311
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of simian/human immunodeficiency virus replication in CD4+ T cells derived from lentiviral-transduced CD34+ hematopoietic cells.
Braun SE; Wong FE; Connole M; Qiu G; Lee L; Gillis J; Lu X; Humeau L; Slepushkin V; Binder GK; Dropulic B; Johnson RP
Mol Ther; 2005 Dec; 12(6):1157-67. PubMed ID: 16168713
[TBL] [Abstract][Full Text] [Related]
7. Long-term survival and concomitant gene expression of ribozyme-transduced CD4+ T-lymphocytes in HIV-infected patients.
Macpherson JL; Boyd MP; Arndt AJ; Todd AV; Fanning GC; Ely JA; Elliott F; Knop A; Raponi M; Murray J; Gerlach W; Sun LQ; Penny R; Symonds GP; Carr A; Cooper DA
J Gene Med; 2005 May; 7(5):552-64. PubMed ID: 15655805
[TBL] [Abstract][Full Text] [Related]
8. Anti-HIV genetic treatment of antigen-specific human CD4 lymphocytes for adoptive immunotherapy of opportunistic infections in AIDS.
Manca F; Fenoglio D; Franchin E; Saverino D; Li Pira G; Buffa F; Bignardi D; Del Pup L; Palù G
Gene Ther; 1997 Nov; 4(11):1216-24. PubMed ID: 9425445
[TBL] [Abstract][Full Text] [Related]
9. An autoregulated dual-function antitat gene for human immunodeficiency virus type 1 gene therapy.
Lisziewicz J; Sun D; Trapnell B; Thomson M; Chang HK; Ensoli B; Peng B
J Virol; 1995 Jan; 69(1):206-12. PubMed ID: 7983711
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of HIV-1 in CEM cells by a potent TAR decoy.
Lee SW; Gallardo HF; Gaspar O; Smith C; Gilboa E
Gene Ther; 1995 Aug; 2(6):377-84. PubMed ID: 7584112
[TBL] [Abstract][Full Text] [Related]
11. Infection and replication of Tat- human immunodeficiency viruses: genetic analyses of LTR and tat mutations in primary and long-term human lymphoid cells.
Chang LJ; Zhang C
Virology; 1995 Aug; 211(1):157-69. PubMed ID: 7645208
[TBL] [Abstract][Full Text] [Related]
12. Long-term protection against HIV-1 infection conferred by tat or rev antisense RNA was affected by the design of the retroviral vector.
Peng H; Callison D; Li P; Burrell C
Virology; 1996 Jun; 220(2):377-89. PubMed ID: 8661389
[TBL] [Abstract][Full Text] [Related]
13. High transdominant RevM10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: implication for gene therapy of AIDS.
Plavec I; Agarwal M; Ho KE; Pineda M; Auten J; Baker J; Matsuzaki H; Escaich S; Bonyhadi M; Böhnlein E
Gene Ther; 1997 Feb; 4(2):128-39. PubMed ID: 9081703
[TBL] [Abstract][Full Text] [Related]
14. SV40-derived vectors provide effective transgene expression and inhibition of HIV-1 using constitutive, conditional,and pol III promoters.
Jayan GC; Cordelier P; Patel C; BouHamdan M; Johnson RP; Lisziewicz J; Pomerantz RJ; Strayer DS
Gene Ther; 2001 Jul; 8(13):1033-42. PubMed ID: 11438838
[TBL] [Abstract][Full Text] [Related]
15. [In vitro and in vivo inhibition of HIV1 replication by retroviral transfer of interferon alpha, beta, or gamma genes: application to gene therapy of AIDS].
Leissner P; Calenda V; Marigliano M; Sanhadji K; Touraine JL; Pavirani A; Mehtali M
Ann Biol Clin (Paris); 1998; 56(2):167-73. PubMed ID: 9754242
[TBL] [Abstract][Full Text] [Related]
16. Block of Tat-mediated transactivation of tumor necrosis factor beta gene expression by polymeric-TAR decoys.
Brother MB; Chang HK; Lisziewicz J; Su D; Murty LC; Ensoli B
Virology; 1996 Aug; 222(1):252-6. PubMed ID: 8806505
[TBL] [Abstract][Full Text] [Related]
17. Rapid protection against human immunodeficiency virus type 1 (HIV-1) replication mediated by high efficiency non-retroviral delivery of genes interfering with HIV-1 tat and gag.
Lori F; Lisziewicz J; Smythe J; Cara A; Bunnag TA; Curiel D; Gallo RC
Gene Ther; 1994 Jan; 1(1):27-31. PubMed ID: 7584056
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of relative promoter strengths of the HIV-1-LTR and a chimeric RSV-LTR in T lymphocytic cells and peripheral blood mononuclear cells: promoters for anti-HIV-1 gene therapies.
Mukhtar M; Duan L; Bagasra O; Pomerantz RJ
Gene Ther; 1996 Aug; 3(8):725-30. PubMed ID: 8854098
[TBL] [Abstract][Full Text] [Related]
19. High level inhibition of HIV replication with combination RNA decoys expressed from an HIV-Tat inducible vector.
Fraisier C; Irvine A; Wrighton C; Craig R; Dzierzak E
Gene Ther; 1998 Dec; 5(12):1665-76. PubMed ID: 10023446
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of HIV-1 replication by a Tat transdominant negative mutant in human peripheral blood lymphocytes from healthy donors and HIV-1-infected patients.
Rossi C; Balboni PG; Betti M; Marconi PC; Bozzini R; Grossi MP; Barbanti-Brodano G; Caputo A
Gene Ther; 1997 Nov; 4(11):1261-9. PubMed ID: 9425451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
